| P2093 | author name string | Harald Hefter | |
| | Dietmar Rosenthal | |
| | Marek Moll | |
| P2860 | cites work | Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. | Q34305982 |
| | Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? | Q34443530 |
| | Clinical presentation and management of antibody-induced failure of botulinum toxin therapy | Q35693989 |
| | Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins--a single cohort 4-year follow-up study | Q36254051 |
| | Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc | Q36370617 |
| | Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. | Q36650003 |
| | Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia | Q36770303 |
| | A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia | Q37325691 |
| | Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis | Q37717924 |
| | EFNS guidelines on diagnosis and treatment of primary dystonias | Q37756221 |
| | Double-blind study of botulinum toxin in spasmodic torticollis | Q39542317 |
| | Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications | Q42926647 |
| | A long-term follow-up of botulinum toxin A in cervical dystonia | Q44590149 |
| | Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay | Q46211591 |
| | Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. | Q46818937 |
| | Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia | Q48281947 |
| | A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. | Q53854678 |
| | Long-term botulinum toxin efficacy, safety, and immunogenicity. | Q54782341 |
| | Development of resistance to botulinum toxin type A in patients with torticollis | Q72476569 |
| | Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences | Q73690419 |
| | Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group | Q77878458 |
| | Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period | Q78609665 |
| | Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia | Q79453150 |
| | Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure | Q81510214 |
| | Xeomin in the treatment of cervical dystonia | Q82210726 |
| | Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B | Q82482580 |
| | Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia | Q83974689 |
| | Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? | Q84265971 |
| P433 | issue | 5 | |
| P921 | main subject | cervical dystonia | Q6152510 |
| P304 | page(s) | 500-506 | |
| P577 | publication date | 2016-05-19 | |
| P1433 | published in | Movement disorders clinical practice | Q27725493 |
| P1476 | title | High Botulinum Toxin-Neutralizing Antibody Prevalence Under Long-Term Cervical Dystonia Treatment | |
| P478 | volume | 3 | |